DAWN — Day One Biopharmaceuticals Share Price
Last trade - 00:00- $1.31bn
- $940.82m
- 23
- 17
- 85
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.77 | ||
| Price to Tang. Book | 3.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.46% | ||
| Return on Equity | -55.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 13.07 | 74.32 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
Directors
- Julie Grant CHM (38)
- Jeremy Bender PRE (49)
- Samuel Blackman CFD (52)
- Charles York CFO (44)
- Mike Preigh CTO
- Lisa Bowers OTH
- Natalie Holles LED (48)
- Scott Garland DRC (53)
- Dan Becker IND (45)
- Derek Di Rocco IND (41)
- Michael Gladstone IND (34)
- John Josey IND (60)
- Saira Ramasastry IND (45)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 1st, 2018
- Public Since
- May 27th, 2021
- No. of Shareholders
- 87,384,856
- No. of Employees
- 155
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 87,377,163
- Address
- 2000 Sierra Point Parkway, Suite 501, BRISBANE, 94080-1930
- Web
- https://dayonebio.com/
- Phone
- +1 6504840899
- Auditors
- Ernst & Young LLP
Upcoming Events for DAWN
Similar to DAWN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:06 UTC, shares in Day One Biopharmaceuticals are trading at $14.96. This share price information is delayed by 15 minutes.
Shares in Day One Biopharmaceuticals last closed at $14.96 and the price had moved by +15.08% over the past 365 days. In terms of relative price strength the Day One Biopharmaceuticals share price has underperformed the S&P500 Index by -4.24% over the past year.
The overall consensus recommendation for Day One Biopharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Day One Biopharmaceuticals does not currently pay a dividend.
Day One Biopharmaceuticals does not currently pay a dividend.
Day One Biopharmaceuticals does not currently pay a dividend.
To buy shares in Day One Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $14.96, shares in Day One Biopharmaceuticals had a market capitalisation of $1.31bn.
Here are the trading details for Day One Biopharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DAWN
Based on an overall assessment of its quality, value and momentum Day One Biopharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Day One Biopharmaceuticals is $35.25. That is 135.63% above the last closing price of $14.96.
Analysts covering Day One Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.63 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Day One Biopharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +31.2%.
As of the last closing price of $14.96, shares in Day One Biopharmaceuticals were trading +10.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Day One Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Day One Biopharmaceuticals' management team is headed by:
- Julie Grant - CHM
- Jeremy Bender - PRE
- Samuel Blackman - CFD
- Charles York - CFO
- Mike Preigh - CTO
- Lisa Bowers - OTH
- Natalie Holles - LED
- Scott Garland - DRC
- Dan Becker - IND
- Derek Di Rocco - IND
- Michael Gladstone - IND
- John Josey - IND
- Saira Ramasastry - IND